Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Irinotecan in Refractory Metastatic Breast Cancer
NCT00072852Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2003
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of irinotecan in breast cancer (2 arms), sponsored by Pfizer. Primary endpoints: Safety of Irinotecan and Efficacy of Irinotecan. Started Nov 2003; status: completed.
02
Drugs
irinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00072852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072852.